| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data |
| 14 Sep 2026 |
8-K: Other Events
In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of i... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel |
| 11 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Cabaletta Bio, Inc. (the “Corporation”), a corporation duly organized and existing under the laws of the State of Delaware pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as ... |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update |
| 14 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 04 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
1. INTRODUCTORY. Cabaletta Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwrite... |
| 04 May 2026 |
8-K: Other Events
Cabaletta intends to present new clinical and translational data from 4 refractory patients that received rese-cel at the lowest dose without preconditioning in the RESET-PV® (pemphigus vulgaris) trial at the American Society of Gene & C... |
| 20 Apr 2026 |
8-K: Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 29 Oct 2025 |
8-K: Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 27 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 09 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure
Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 12 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Cabaletta Bio, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (i) 39,200,000 shares (the “Shares”) of its common... |
Loading...